Want to see SPRY full AI Analyst Report?
SPRY Stock Chart & Stats
$5.94
-$0.17(-2.86%)
At close: 4:00 PM EDT
$5.94
-$0.17(-2.86%)
Day’s Range― - ―
52-Week Range$5.35 - $18.00
Previous CloseN/A
Volume674.69K
Average Volume (3M)2.13M
Market Cap
$578.94M
Enterprise Value$1.06B
Total Cash (Recent Filing)$200.97M
Total Debt (Recent Filing)$96.52M
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Aug 12, 2026EPS Estimate
-0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.01
Shares Outstanding99,303,260
10 Day Avg. Volume2,563,913
30 Day Avg. Volume2,125,274
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)10.05
Price to Sales (P/S)13.63
P/FCF Ratio-6.71
Enterprise Value/Market Cap1.82
Enterprise Value/Revenue10.66
Enterprise Value/Gross Profit13.83
Enterprise Value/Ebitda-5.49
Forecast
1Y Price Target
$30.00Price Target Upside405.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.73
Revenue Forecast (FY)$139.82M
Bulls Say, Bears Say
Bulls Say
High Gross MarginA ~75.8% gross margin indicates strong product-level economics from neffy’s needle-free delivery. Durable high margins imply that incremental volume can convert to significant operating leverage as SG&A normalizes, supporting long-term profitability potential once scale and refill rates improve.
Rapid Commercial Traction And Installed Base GrowthSteep prescription and installed-base growth (3x volume YoY; ~120k patients) and expanding prescriber adoption demonstrate durable demand. A growing refill pool and expanded field force increase recurring revenue potential and predictability as back-to-school/refill cycles mature over the coming quarters.
Regulatory And International ExpansionRemoval of the FDA age restriction and approvals in Canada and the EU materially expand the addressable market and reduce regulatory uncertainty. Partner-led launches (e.g., ALK) and pediatric label expansion create durable growth levers beyond U.S. retail volumes and support multi-region commercialization.
Bears Say
Large Cash Burn And Negative Operating Cash FlowSustained negative operating cash flow (TTM ~-$175M) and negative free cash flow reflect material cash burn to fund commercialization. Even with recent cash balances, persistent high burn raises refinancing risk and makes achievement of management's mid‑2027 breakeven timeline dependent on execution and payer progress.
High SG&A And Deep Net LossesHeavy commercial and marketing spend (Q1 SG&A $72.2M) have driven large, persistent losses and deeply negative margins. Until revenue scale materializes or SG&A efficiency improves, profitability remains distant, increasing dilution or financing needs and constraining durable return generation.
Prior-authorization Friction And Prescription AbandonmentSignificant prior-authorization barriers (~43% of covered lives still face PA) and ~22–23% abandonment materially reduce conversion of written scripts to filled prescriptions. These structural access frictions raise acquisition costs and make revenue realization highly dependent on payer decisions and pharmacy workflows.
ARS Pharmaceuticals News
SPRY FAQ
What was Ars Pharmaceuticals, Inc.’s price range in the past 12 months?
Ars Pharmaceuticals, Inc. lowest stock price was $5.35 and its highest was $18.00 in the past 12 months.
What is Ars Pharmaceuticals, Inc.’s market cap?
Ars Pharmaceuticals, Inc.’s market cap is $578.94M.
When is Ars Pharmaceuticals, Inc.’s upcoming earnings report date?
Ars Pharmaceuticals, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 12 days.
How were Ars Pharmaceuticals, Inc.’s earnings last quarter?
Ars Pharmaceuticals, Inc. released its earnings results on May 15, 2026. The company reported -$0.61 earnings per share for the quarter, missing the consensus estimate of -$0.516 by -$0.094.
Is Ars Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Ars Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Ars Pharmaceuticals, Inc. pay dividends?
Ars Pharmaceuticals, Inc. does not currently pay dividends.
What is Ars Pharmaceuticals, Inc.’s EPS estimate?
Ars Pharmaceuticals, Inc.’s EPS estimate is -0.48.
How many shares outstanding does Ars Pharmaceuticals, Inc. have?
Ars Pharmaceuticals, Inc. has 99,303,260 shares outstanding.
What happened to Ars Pharmaceuticals, Inc.’s price movement after its last earnings report?
Ars Pharmaceuticals, Inc. reported an EPS of -$0.61 in its last earnings report, missing expectations of -$0.516. Following the earnings report the stock price went down -6.486%.
Which hedge fund is a major shareholder of Ars Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in SPRY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ARS Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$30.00 (405.05% Upside)
$30.00 (405.05% Upside)
Blogger Sentiment
Bullish
SPRY Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 339.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 3.5%
Last 30 Days ▲ 3.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.85%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-12.14%
Trailing 12-Months
Company Description
Ars Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.
SPRY Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and meaningful operational progress (robust YoY prescription and revenue growth, regulatory approvals, expanded coverage and new affordability programs), backed by a healthy cash balance and a clear plan to scale through the back-to-school season and refill cycles. However, execution risks remain: significant SG&A spend and cash burn, prior-authorization friction that still limits access for a meaningful portion of covered lives, notable prescription abandonment, and uncertainty around timing of key payer decisions (e.g., CVS Caremark). On balance, the positives around growth, access expansion, regulatory wins and commercial initiatives outweigh the operational challenges, but the company remains execution- and timing-dependent over the coming quarters.View all SPRY earnings summariesSPRY Stock 12 Month Forecast
Average Price Target
$30.00
▲(405.05% Upside)
Technical Analysis
Trevi Therapeutics
―
Oric Pharmaceuticals
―
Pharming Group
―
Maze Therapeutics, Inc.
―
Sionna Therapeutics, Inc.
―
Ownership Overview
50.06% Insiders
6.93% Mutual Funds
1.75% Other Institutional Investors
31.88% Public Companies and
Individual Investors